Loading...
C4 Therapeutics Q1 2025 Earnings Report
C4 Therapeutics reported a decrease in net loss and total assets, with an increase in revenue from collaboration agreements for Q1 2025.
Key Takeaways
C4 Therapeutics, Inc. reported a net loss of $26.322 million for the three months ended March 31, 2025, an improvement from the $28.361 million net loss in the same period last year. Revenue from collaboration agreements significantly increased to $7.238 million from $3.039 million year-over-year. Total assets decreased to $319.524 million from $349.602 million at the end of 2024.
Net loss improved to $26.322 million in Q1 2025 from $28.361 million in Q1 2024.
Revenue from collaboration agreements more than doubled, reaching $7.238 million in Q1 2025 compared to $3.039 million in Q1 2024.
Research and development expenses increased to $27.072 million in Q1 2025 from $22.533 million in Q1 2024, driven by progress in collaboration programs and clinical trials.
General and administrative expenses decreased to $9.330 million in Q1 2025 from $10.288 million in Q1 2024, primarily due to restructuring activities in January 2024.
Revenue by Segment
Forward Guidance
C4 Therapeutics expects to incur significant expenses and operating losses for the foreseeable future as it advances its preclinical programs and product candidates through clinical development. The company anticipates its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027.
Positive Outlook
- Continued progress in ongoing first-in-human Phase 1/2 trials.
- Initiation of later-stage development and potential registrational trials for product candidates.
- Advancement of additional product candidates into preclinical and clinical development.
- Continued investment in the proprietary TORPEDO platform.
- Potential for additional research support or milestone payments from existing collaboration partners.
Challenges Ahead
- Significant increase in expenses and operating losses for the foreseeable future.
- Uncertainty in the timing and outcome of preclinical testing and clinical trials.
- Potential for delays in obtaining marketing approvals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...